The premium price raised eyebrows even among MedImmune shareholders who had been urging the company to sell. (See BioWorld Today, April 24, 2007.)

auth123#Randy Osborne

We expect AbbVie to treat this as the high priority it deserves."

While we do not expect a generic Advair in the near term as the regulatory path for generic respiratory drugs are challenging, we believe GSK incentivized to move away from Advair to Breo well ahead of any generic entrants."

The $25 million Series A round took place in 2008. (See BioWorld Today, March 5, 2008, and July 14, 2010.)

Zalicus will control the timing and amount of any common stock sales to Lincoln Park.

Array's stock (NASDAQ:ARRY) closed Tuesday at $5.24, down 56 cents.

CTP354, at an earlier stage, targets spasticity and neuropathic pain.

Randy Osborne

but there was interest from other pharmaceutical companies," he said.

approaching biopharma companies and medical devices companies about purchasing their royalty streams as a way of financing."

In an open-label Phase II study conducted in children with simplex, recessive dystrophic EB or junctional EB, SD-101 application resulted in complete closure of 88 percent of target chronic lesions within one month.

The company uses its G-Technology for sustained-release delivery of existing drugs.

Keeping those at bay early, making those early decisions to assure your production is efficient and effective and your cost of goods is low" can help offset El Salvador-type surprises.

The convention ends Thursday.

that other companies will do."

By Randy Osborne Staff Writer CHICAGO – Officials from the China Food and Drug Administration (CFDA) stammered through a question-and-answer period in which the audience sought the agency's definition of an "innovative" drug, its stance on orphan therapies and its policy with regard to biosimilars, during the first day of the BIO 2013 International Convention here

The convention ends Thursday.

dual-corrector regimen," in his view.